Qualigen-Logo-Tag.png
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
14 nov. 2023 16h30 HE | Qualigen Therapeutics, Inc.
Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates...